Old Web
English
Sign In
Acemap
>
Paper
>
MA 02.11 A Phase I Trial of Erlotinib and Onalespib in EGFR-mutant NSCLC: Focus on EGFR Exon 20 Insertions
MA 02.11 A Phase I Trial of Erlotinib and Onalespib in EGFR-mutant NSCLC: Focus on EGFR Exon 20 Insertions
2017
Jonathan W. Riess
Karen L. Reckamp
Jeffrey Longmate
Karen Kelly
David R. Gandara
P. C. Mack
Edward M. Newman
Primo N. Lara
Keywords:
Exon
Erlotinib
Pathology
Mutant
Medicine
Correction
Source
Cite
Save
Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI
[]